电视辅助胸腔镜下解剖性肺切除治疗I期肺癌的临床效果

目的 探讨电视辅助胸腔镜下解剖性肺切除治疗Ⅰ期肺癌的临床效果。方法 采用回顾性研究方法,选取2015年5月至2017年1月广西医科大学附属肿瘤医院收治的I期肺癌患者84例,按照手术方法不同将患者分为两组:观察组和对照组,每组各42例。观察组患者实施电视辅助胸腔镜下解剖性肺切除术治疗,对照组患者给予传统开胸肺叶切除术治疗。比较两组患者的住院时间、切口长度、术中出血量、手术时间、1年和3年生存情况及生活质量评分(SF-36生活量表)变化。结果 观察组患者的住院时间短于对照组(6. 13±1. 46 vs. 10. 39±2. 41 d),切口长度小于对照组(4. 38±1. 09 vs. 11. 84±3. 25 cm),术中出血量少于对照组(284. 62±54. 21 vs. 397. 57±61. 49 ml),差异均具有统计学意义(P <0. 05);而两组手术时间比较(165. 28±33. 24 vs. 156. 39±30. 92 min),差异无统计学意义(P> 0. 05)。观察组患者的1、3年生存率[97. 62%(41/42)、90. 48%(38/42)]均高于对照组[88. 10%(37/42)、76. 19%(32/42)],但差异无统计学意义(P> 0. 05)。观察组患者的各项生活质量评分[精神健康(75. 42±6. 87 vs 61. 30±4. 15分)、情感职能(81. 38±7. 15 vs. 73. 49±5. 76分)、社会功能(82. 67±5. 78 vs. 75. 42±4. 35分)、一般健康状况(79. 49±6. 17 vs.70. 31±5. 04分)、精力(84. 37±5. 45 vs. 74. 13±6. 07分)、生理职能(86. 52±6. 88 vs. 76. 93±6. 42分)、躯体疼痛(83. 46±7. 49 vs. 74. 33±5. 79分)、生理功能(70. 39±4. 31 vs. 61. 38±3. 56分)]均高于对照组,且差异具有统计学意义(P <0. 05)。结论 与传统开胸肺叶切除术相比,电视辅助胸腔镜下解剖性肺切除治疗I期肺癌手术损伤更小、短期生存率更高,且有助于提高患者术后生活质量水平,这对改善患者预后有重要意义,值得临床推广应用。     

经络艾灸防治乳腺癌根治术后患侧上肢水肿的效果评价

目的观察循经艾灸预防乳腺癌患者根治术后上肢水肿的效果。方法采用便利抽样法选取乳腺外科乳腺癌根治术的患者150例,随机分为对照组和观察组,每组75例。对照组行常规护理,观察组在对照组基础上在手术侧上肢循经艾灸。于术前1 d、术后第14天和术后1个月,测量两组患者患侧上肢水肿程度。结果观察组术后患侧上肢水肿发生率低于对照组(P<0.05)。结论术后循经艾灸可有效预防乳腺癌根治术后患侧上肢水肿,提高患者舒适度。     

TACE 术前天冬氨酸氨基转移酶与淋巴细胞比值对原发性肝癌并门脉癌栓患者预后预测的价值

目的 探讨肝动脉化疗栓塞（transcatheter arterial chemoembolization，TACE）术前天冬氨酸氨基转移酶与淋巴细胞比值（aspartate aminotransferase to lymphocyte ratio index，ALRI）在原发性肝癌并门脉癌栓（primary liver cancer-portal vein tumor thrombosis，PLC-PVTT）患者预后预测中的价值。方法 选取2013年11月21日至2018年8月22日于广西医科大学附属肿瘤医院接受TACE治疗的175例PLC-PVTT患者为研究对象。采用时间依赖性ROC曲线确定ALRI的最佳临界值。采用Cox 回归模型分析总生存期（overall survival，OS）的独立预测因素，Kaplan-Meier法计算生存率。结果 ROC曲线显示，ALRI的最佳临界值为49.37，对应曲线下面积为0.71。Kaplan-Meier分析显示，ALRI>49.37的患者OS较ALRI≤49.37的患者短（P=0.003）。Cox 回归分析结果显示，ALRI>49.37、行1次以上TACE治疗、Child-Pugh分级B级、凝血酶原时间≥13 s是患者TACE术后OS的独立危险因素（均P＜0.05）。结论 TACE术前ALRI>49.37是PLC-PVTT患者OS的独立危险因素。     

Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302)

BackgroundFOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with previously treated metastatic colorectal cancer (mCRC). Our aim was to investigate efficacy and tolerability of this combination in the first line.Patients and MethodsPatients with untreated documented mCRC received aflibercept plus FOLFIRI every 14 days until progression or unacceptable toxicity in an open, phase II single-arm, multicenter trial. The primary endpoint was the 6-month PFS rate. Secondary endpoints were OS and tolerability. A 2-step Simon design was used with H₀: 55% and H₁= 75%. Data were analyzed in intention to treat.ResultsForty-one patients were included, and 40 were analyzed (1 consent withdrawal) in 9 French centers between October 2014 and February 2017. The median age was 65 years (range, 46-81 years), 55% had ≥ 2 metastatic sites, and 50% and 15% had RAS and BRAF mutations, respectively. Twenty-two (54.5%; 95% confidence interval, 38.9%-68.5%) patients were alive and non-progressive at 6 months. FOLFIRI + aflibercept was considered ineffective, resulting in the cessation of inclusions. The median follow-up was 34 months. The overall response rate was 55%, and the disease control rate was 80%. The median duration of treatment was 5.3 months; the median PFS and OS were 8.2 and 18.6 months, respectively. Grade 3 to 4 adverse events were mainly gastrointestinal (47.5%) and vascular (32.5%). Of the patients, 87.5% had at least 1 dose modification.ConclusionAlthough the primary objective was not met, first-line FOLFIRI + aflibercept for mCRC leads to median PFS and OS close to those reported with classical doublet and targeted agents, but with significant toxicities needing dose reduction.     

甲状腺乳头状微小癌的诊治分析

目的探讨甲状腺乳头状微小癌的临床特征、诊断及治疗方式。方法回顾性分析1985～ 2 0 0 2年间我院收治并经病理证实的甲状腺乳头状微小癌 89例患者的临床资料。结果随访 89例 ,时间 5～ 196个月 ,平均 6 8 9个月。复发 5例 ,无死亡 ,未发现远处转移。因甲状腺良性病变手术而发现微小癌 38例 ,另 5 1例术前怀疑为癌 ,经活检发现微小癌。颈部淋巴结转移 4 0例 ,最多发生在颈深上、中组和气管食管沟组淋巴结。腺叶多发结节转移的发生率显著高于单发结节。不同大小的原发肿瘤 (≤ 5mm ;>5mm)在颈部淋巴结转移的发生率其差异有显著性。是否可触及肿大淋巴结对局部复发率的影响差异有显著性。结论术前触诊、B超检查、术中探查及冰冻组织切片对提高甲状腺乳头状微小癌的诊断非常重要。根据病情选择不同的切除范围 ,疗效是同样的。建议区分两类甲状腺乳头状微小癌 :一类良性进展 ,应以保守性手术为主 ;另一类侵袭性进展 ,有不良预后 ,应行积极的手术方式。     

外周炎症时大鼠背根神经节细胞μ-和κ-阿片受体mRNA的表达

目的观察外周炎症时大鼠背根神经节(dorsalrootganglion,DRG)细胞μ-和κ-阿片受体mRNA表达的变化。方法用角叉菜胶(carrageenan,CAR)在大鼠右后足皮下注射产生外周炎症,分别于正常和炎症后6、12、24和72h取右L4~5DRG。用原位杂交的方法观察正常及炎症期间DRG细胞μ-和κ-阿片受体mRNA表达的变化。结果正常大鼠的部分DRG细胞内可见μ-和κ-阿片受体mRNA表达。外周炎症后6h,表达μ-和κ-阿片受体mRNA的DRG细胞的数和μ-和κ-阿片受体mRNA表达量增加,24h表达量最高,72h下降至正常。结论外周炎症能使大鼠DRG细胞μ-和κ-阿片受体mRNA表达增加。提示外周炎症时大鼠DRG细胞μ-和κ-阿片受体合成增加。为阿片类物质应用于外周镇痛提供理论依据。     

基于随机森林算法的肿瘤科护士工作倦怠影响因素分析:一项多中心研究

目的 采用随机森林算法探讨肿瘤科护士工作倦怠的影响因素。 方法 于2018年3—8月对广西全区25所三级综合医院和专科医院1253名肿瘤科护士采用一般资料问卷、工作倦怠量表、心理资本量表进行横断面调查,分析其工作倦怠现状及其影响因素,使用随机森林分析对可能影响肿瘤科护士工作倦怠的自变量进行重要性排序,将袋外估算误差率最小的变量集纳入logistic回归模型,分析自变量的作用方向和相对危险度。 结果 逐步随机森林分析显示,变量数为8时的袋外估算误差率最低,重要性排名前8的变量依次为收入状况满意度、护患关系满意度、从事肿瘤科护理工作年限、心理资本、年龄、参加院级以上培训次数、群众认可与尊重程度、夜班频次;Logistic回归分析显示,收入状况满意度为一般（OR=1.228,95%CI:1.019~1.497）和不满意或很不满意（OR=1.276,95%CI:1.005~1.621）、护患关系满意度为一般（OR=1.158,95%CI:1.036~1.295）和不满意或很不满意组（OR=1.196,95%CI:1.020~1.402）、从事肿瘤科护理工作5~10年（OR=1.365,95%CI:1.001~1.860）和>10年（OR=1.702,95%CI:1.222~2.371）、心理资本（OR=0.904,95%CI:0.824~0.991）、年龄25~30岁（OR=1.347, 95%CI:1.010~1.797）和>30岁（OR=1.397,95%CI:1.007~1.937）、参加院级以上培训次数1~2次/年（OR=1.107,95%CI:1.008~1.217）、群众认可与尊重程度为一般（OR=1.105,95%CI:1.008~1.212）和不尊重（OR=1.260,95%CI:1.010~1.572）、夜班频次<1次/周（OR=1.115,95%CI:1.025~1.213）和≥1次/周（OR=1.397,95%CI:1.146~1.702）是肿瘤科护士工作倦怠的独立危险因素（P<0.05）。 结论 影响肿瘤科护士工作倦怠的前8位因素依次为收入状况满意度、护患关系满意度、从事肿瘤科护理工作年限、心理资本、年龄、参加院级以上培训次数、群众认可与尊重程度、夜班频次,建议医院和护理管理者应制定相应策略,减少肿瘤科护士工作倦怠。     

Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report

Patients with non‐small cell lung cancer (NSCLC) containing ROS1 fusions can have a marked response to the ROS1‐targeted tyrosine kinase inhibitors (TKIs), such as crizotinib. Common resistance mechanisms of ROS1‐fusion targeted therapy are acquired mutations in ROS1. Along with the use of next‐generation sequencing in the clinical management of patients with NSCLC during sequential targeted therapy, many mechanisms of acquired resistance have been discovered in patients with activated tyrosine kinase receptors. Besides acquired resistance mutations, bypass mechanisms of resistance to epidermal growth factor receptor (EGFR)‐TKI treatment are common in patients with EGFR mutations. Here we describe a patient with metastatic lung adenocarcinoma with CD74‐ROS1 fusion who initially responded to crizotinib and then developed resistance by the acquired mutation of D1228N in the MET kinase domain, which showed short‐term disease control for cabozantinib.Key Points

• The D1228N point mutation of MET is an acquired mutation for crizotinib resistance.
• The patient obtained short‐term clinical benefit from cabozantinib therapy after resistance to crizotinib.
• The clinical use of next‐generation sequencing could maximize the benefits of precision medicine in patients with cancer.